The European Parliament launched its revised EU pharmaceutical package in the first quarter of 2023. The fragmentation of EU health research and development, a lack of transparency and a disparity between public investment and clinical output are among the weaknesses identified. Possible solutions include the creation of a large-scale European biomedical infrastructure, and a series of targeted strategies to improve the coordination of EU health research and reprioritise areas of healthcare with unmet therapeutic needs.

Committee on Environment, Public Health and Food Safety

European Parliament

Public health (T2)

HEALTH AND ENVIRONMENT (T1)

health care

pharmaceutical legislation

pharmaceutical industry

health legislation

Towards a new EU pharmaceutical strategy - English

https://api.multimedia.europarl.europa.eu/documents/20125/69641109/1681726516353_EPBL0903202301_ENChapters%5BSD-EN%5D.srt